Addition of Anti-Angiogenetic Therapy with Bevacizumab to Chemo- and Radiotherapy for Leptomeningeal Metastases in Primary Brain Tumors.
Leptomeningeal dissemination of a primary brain tumor is a condition which is challenging to treat, as it often occurs in rather late disease stages in highly pretreated patients. Its prognosis is dismal and there is still no accepted standard of care. We report here a good clinical effect with a pa...
Main Authors: | Michael C Burger, Pia S Zeiner, Kolja Jahnke, Marlies Wagner, Michel Mittelbronn, Joachim P Steinbach |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2016-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC4890753?pdf=render |
Similar Items
-
Combination of Atezolizumab, Bevacizumab, and Chemotherapy (IMpower 150) in a Patient With NSCLC Having Leptomeningeal Metastases
by: Jordi Remon, MD, et al.
Published: (2021-01-01) -
Impact of New Systemic Treatment and Radiotherapy in Melanoma Patients with Leptomeningeal Metastases
by: Pauline Tétu, et al.
Published: (2020-09-01) -
Comparison of angiogenetic effects of different dose fractionated radiotherapy on rectal cancer cells
by: TONG Chaoxu, et al.
Published: (2022-10-01) -
Helical tomotherapy in patients with leptomeningeal metastases
by: Schiopu SRI, et al.
Published: (2018-12-01) -
Prolonged Response and Restoration of Functional Independence with Bevacizumab plus Vinorelbine as Third-Line Treatment for Breast Cancer-Related Leptomeningeal Metastases
by: Emilie Le Rhun, et al.
Published: (2015-02-01)